473 related articles for article (PubMed ID: 34572737)
21. TRAIL/NF-κB/CX3CL1 Mediated Onco-Immuno Crosstalk Leading to TRAIL Resistance of Pancreatic Cancer Cell Lines.
Geismann C; Erhart W; Grohmann F; Schreiber S; Schneider G; Schäfer H; Arlt A
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29867042
[TBL] [Abstract][Full Text] [Related]
22. NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation.
Zhuang Z; Li H; Lee H; Aguilar M; Gocho T; Ju H; Iida T; Ling J; Fu J; Wu M; Sun Y; Lu Y; Chiao PJ
Cancer Lett; 2017 Dec; 411():44-56. PubMed ID: 28951128
[TBL] [Abstract][Full Text] [Related]
23. Knocking down GALNT6 promotes pyroptosis of pancreatic ductal adenocarcinoma cells through NF-κB/NLRP3/GSDMD and GSDME signaling pathway.
Ding M; Liu J; Lv H; Zhu Y; Chen Y; Peng H; Fan S; Chen X
Front Oncol; 2023; 13():1097772. PubMed ID: 36925932
[TBL] [Abstract][Full Text] [Related]
24. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic cancer.
Yin H; Pu N; Chen Q; Zhang J; Zhao G; Xu X; Wang D; Kuang T; Jin D; Lou W; Wu W
Cell Death Dis; 2021 Oct; 12(11):1033. PubMed ID: 34718325
[TBL] [Abstract][Full Text] [Related]
25. NF-κB Dependent Chemokine Signaling in Pancreatic Cancer.
Geismann C; Schäfer H; Gundlach JP; Hauser C; Egberts JH; Schneider G; Arlt A
Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31561620
[TBL] [Abstract][Full Text] [Related]
26. Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-κB-related signaling.
Kuo SH; Yang SH; Wei MF; Lee HW; Tien YW; Cheng AL; Yeh KH
Cancer Cell Int; 2021 Aug; 21(1):436. PubMed ID: 34412631
[TBL] [Abstract][Full Text] [Related]
27. Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy.
Zhang Z; Cheng L; Li J; Qiao Q; Karki A; Allison DB; Shaker N; Li K; Utturkar SM; Atallah Lanman NM; Rao X; Rychahou P; He D; Konieczny SF; Wang C; Shao Q; Evers BM; Liu X
Cancer Res; 2022 Oct; 82(19):3532-3548. PubMed ID: 35950917
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of Survival Pathways MAPK and NF-kB Triggers Apoptosis in Pancreatic Ductal Adenocarcinoma Cells via Suppression of Autophagy.
Papademetrio DL; Lompardía SL; Simunovich T; Costantino S; Mihalez CY; Cavaliere V; Álvarez É
Target Oncol; 2016 Apr; 11(2):183-95. PubMed ID: 26373299
[TBL] [Abstract][Full Text] [Related]
29. YEATS2 regulates the activation of TAK1/NF-κB pathway and is critical for pancreatic ductal adenocarcinoma cell survival.
Sheng H; Zheng F; Lan T; Chen HF; Xu CY; Wang SW; Weng YY; Xu LF; Zhang F
Cell Biol Toxicol; 2023 Jun; 39(3):1-16. PubMed ID: 34686948
[TBL] [Abstract][Full Text] [Related]
30. Role of CCL20 mediated immune cell recruitment in NF-κB mediated TRAIL resistance of pancreatic cancer.
Geismann C; Grohmann F; Dreher A; Häsler R; Rosenstiel P; Legler K; Hauser C; Egberts JH; Sipos B; Schreiber S; Linkermann A; Hassan Z; Schneider G; Schäfer H; Arlt A
Biochim Biophys Acta Mol Cell Res; 2017 May; 1864(5):782-796. PubMed ID: 28188806
[TBL] [Abstract][Full Text] [Related]
31. Dysbindin promotes pancreatic ductal adenocarcinoma metastasis by activating NF-κB/MDM2 via miR-342-3p.
Zhu D; Zheng S; Fang C; Guo X; Han D; Tang M; Fu H; Jiang M; Xie N; Nie Y; Yao X; Chen Y
Cancer Lett; 2020 May; 477():107-121. PubMed ID: 32120026
[TBL] [Abstract][Full Text] [Related]
32. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
[TBL] [Abstract][Full Text] [Related]
33. Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Zhang D; Li L; Jiang H; Knolhoff BL; Lockhart AC; Wang-Gillam A; DeNardo DG; Ruzinova MB; Lim KH
Clin Cancer Res; 2017 Apr; 23(7):1748-1759. PubMed ID: 27702822
[No Abstract] [Full Text] [Related]
34. Increased SPRY1 expression activates NF-κB signaling and promotes pancreatic cancer progression by recruiting neutrophils and macrophages through CXCL12-CXCR4 axis.
Shi T; Li X; Zheng J; Duan Z; Ooi YY; Gao Y; Wang Q; Yang J; Wang L; Yao L
Cell Oncol (Dordr); 2023 Aug; 46(4):969-985. PubMed ID: 37014552
[TBL] [Abstract][Full Text] [Related]
35. Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice.
Maniati E; Bossard M; Cook N; Candido JB; Emami-Shahri N; Nedospasov SA; Balkwill FR; Tuveson DA; Hagemann T
J Clin Invest; 2011 Dec; 121(12):4685-99. PubMed ID: 22056382
[TBL] [Abstract][Full Text] [Related]
36. Galectin-3 Mediates Tumor Cell-Stroma Interactions by Activating Pancreatic Stellate Cells to Produce Cytokines via Integrin Signaling.
Zhao W; Ajani JA; Sushovan G; Ochi N; Hwang R; Hafley M; Johnson RL; Bresalier RS; Logsdon CD; Zhang Z; Song S
Gastroenterology; 2018 Apr; 154(5):1524-1537.e6. PubMed ID: 29274868
[TBL] [Abstract][Full Text] [Related]
37. Novel Seleno-Aspirinyl Compound AS-10 Induces Apoptosis, G1 Arrest of Pancreatic Ductal Adenocarcinoma Cells, Inhibits Their NF-κB Signaling, and Synergizes with Gemcitabine Cytotoxicity.
Karelia DN; Kim S; K Pandey M; Plano D; Amin S; Lu J; Sharma AK
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34067020
[TBL] [Abstract][Full Text] [Related]
38. OXCT1 Enhances Gemcitabine Resistance Through NF-κB Pathway in Pancreatic Ductal Adenocarcinoma.
Ding J; Li H; Liu Y; Xie Y; Yu J; Sun H; Xiao D; Zhou Y; Bao L; Wang H; Gao C
Front Oncol; 2021; 11():698302. PubMed ID: 34804914
[TBL] [Abstract][Full Text] [Related]
39. Identification of non-canonical NF-κB signaling as a critical mediator of Smac mimetic-stimulated migration and invasion of glioblastoma cells.
Tchoghandjian A; Jennewein C; Eckhardt I; Rajalingam K; Fulda S
Cell Death Dis; 2013 Mar; 4(3):e564. PubMed ID: 23538445
[TBL] [Abstract][Full Text] [Related]
40. GATA4 Regulates Inflammation-Driven Pancreatic Ductal Adenocarcinoma Progression.
Jiang W; Chen C; Huang L; Shen J; Yang L
Front Cell Dev Biol; 2021; 9():640391. PubMed ID: 33996796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
